IPSCCentury Therapeutics, Inc.

IPSC Stock Price, Valuation & Chart | Century Therapeutics, Inc.

Compare

$2.110+0.08 (+3.94%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology IPSC intrinsic value IPSC calculated fair value vs price

Overview Financials Dividends Ratios

IPSC Historical price chart

IPSC Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization182.66M

PE Ratio-1.99

EPS-1.06

Trading Volume465.33K

Today's High/Low2.13/2.03

Dividend Yield0.00

52 Week High/Low3.04/0.43

Shares Outstanding86.57M

IPSC Financial Statement

IPSC Analyst ratings

IPSC Analysis & performance metrics

IPSC Company profile

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The…

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It…

IPSC Management team

Name

Position

Brent Pfeiffenberger M.B.A., Pharm.D.CEO

President, Chief Executive Officer & Director

Adrienne Farid Ph.D.

Chief Development Officer & Head of Early Development

Michael Naso Ph.D.

Senior Vice President of Cell Engineering

Katja Buhrer

SVice President, Head of Corporate Affairs & Strategy

Gregory Russotti Ph.D.CTO

Chief Technology & Manufacturing Officer

Morgan Conn Ph.D.CFO

Chief Financial Officer

Douglas Carr CPA

Senior Vice President of Finance & Operations and Secretary

Chad A. Cowan Ph.D.

Chief Scientific Officer

Name

Position

Brent Pfeiffenberger M.B.A., Pharm.D.CEO

President, Chief Executive Officer & Director

Adrienne Farid Ph.D.

Chief Development Officer & Head of Early Development

Michael Naso Ph.D.

Senior Vice President of Cell Engineering

Katja Buhrer

SVice President, Head of Corporate Affairs & Strategy

Gregory Russotti Ph.D.CTO

Chief Technology & Manufacturing Officer

Morgan Conn Ph.D.CFO

Chief Financial Officer

Douglas Carr CPA

Senior Vice President of Finance & Operations and Secretary

Chad A. Cowan Ph.D.

Chief Scientific Officer

Management Team

Brent Pfeiffenberger M.B.A., Pharm.D.CEO

President, Chief Executive Officer & Director

Adrienne Farid Ph.D.

Chief Development Officer & Head of Early Development

Michael Naso Ph.D.

Senior Vice President of Cell Engineering

Katja Buhrer

SVice President, Head of Corporate Affairs & Strategy

Gregory Russotti Ph.D.CTO

Chief Technology & Manufacturing Officer

Morgan Conn Ph.D.CFO

Chief Financial Officer

Douglas Carr CPA

Senior Vice President of Finance & Operations and Secretary

Chad A. Cowan Ph.D.

Chief Scientific Officer

Management

Brent Pfeiffenberger M.B.A., Pharm.D.CEO

President, Chief Executive Officer & Director

Adrienne Farid Ph.D.

Chief Development Officer & Head of Early Development

Michael Naso Ph.D.

Senior Vice President of Cell Engineering

Katja Buhrer

SVice President, Head of Corporate Affairs & Strategy

Gregory Russotti Ph.D.CTO

Chief Technology & Manufacturing Officer

Morgan Conn Ph.D.CFO

Chief Financial Officer

Douglas Carr CPA

Senior Vice President of Finance & Operations and Secretary

Chad A. Cowan Ph.D.

Chief Scientific Officer

Total 8 executives

IPSC Frequently asked questions

What is Century Therapeutics, Inc. (IPSC) Stock Price?

Current stock price of Century Therapeutics, Inc. (IPSC) stock is $2.110. The stock price is +3.94% higher in the session. The intraday range can be seen from this page. Volume of Century Therapeutics, Inc. (IPSC) stock is 465.33K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Century Therapeutics, Inc. (IPSC) stock price going up or down today?

The stock price of Century Therapeutics, Inc. (IPSC) can change with earnings, company news, and overall market sentiment. Century Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Century Therapeutics, Inc. stock expensive at its current price?

Whether Century Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IPSC on this page is -1.99. EPS on this page is -1.06. Compare those figures with peers and growth expectations before deciding if the current Century Therapeutics, Inc. price is justified.

How has the stock price of Century Therapeutics, Inc. (IPSC) performed historically?

Historical performance for Century Therapeutics, Inc. (IPSC) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IPSC reacted to past earnings and market events.

Should I buy Century Therapeutics, Inc. (IPSC) stock, at this price?

Buying Century Therapeutics, Inc. (IPSC) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.